METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48

• Main Authors: ANDERSEN, HENRIK, SUNE, HANSEN, THOMAS, KRUSE, AXE, FRANK, URBAN, LAU, JESPER, SHAPIRA, BARRY, ZVI, JUDGE, LUKE, MILBURN, UYEDA, ROY, TERUYUKI, OLSEN, OLE, HVILSTED, HOLSWORTH, DANIEL, DALE, MOELLER, NIELS, PETER, HUNDAHL, GE, YU, JONES, TODD, KEVIN, IVERSON, LARS, FOGH, RIPKA, WILLIAM, CHARLES
• Format: Patent
• Language: English; French
• Published: 08.11.2001
• Edition: 7
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTP alpha , PTP epsilon , PTP mu , PTP delta , PTP sigma , PTP zeta , PTP beta , PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function. L'invention concerne un procédé d'inhibition d'un membre d'une famille de protéine tyrosine phosphatases (PTPases, PTP), telles que PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTP alpha , PTP epsilon , PTP mu , PTP delta , PTP sigma , PTP zeta , PTP beta , PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR et HePTP, qui consiste à exposer ledit membre de la famille Ptpase par l'administration à un hôte ou autrement, à au moins un composé présentant certaines caractéristiques physiques et spatiales permettant l'interaction dudit composé avec les composés spécifiques du site actif de PTP1B et/ou TC-PTP. Lesdits composés sont indiqués dans la gestion ou le traitement d'une gamme étendue de maladies, telles que les maladies autoimmunes, l'inflammation chronique et aiguë, l'ostéoporose, diverses formes de cancers et des affections malignes, le diabète de type I et II ainsi que dans l'isolement de PTPases et dans l'élucidation ou l'élucidation avancée de leur fonction biologique.